Article
Microbiology
Suraj Arora, Vishakha Grover, Priyanka Saluja, Youssef Abdullah Algarni, Shahabe Abullais Saquib, Shaik Mohammed Asif, Kavita Batra, Mohammed Y. Alshahrani, Gotam Das, Rajni Jain, Anchal Ohri
Summary: This review summarizes the structural or virologic characteristics, burden, and epidemiology of the Omicron variant and its potential to evade the immune response. The Omicron variant of COVID-19 has highly infectious and transmissible characteristics, making it a significant global concern.
Article
Chemistry, Multidisciplinary
Bryan Dafniet, Natacha Cerisier, Batiste Boezio, Anaelle Clary, Pierre Ducrot, Thierry Dorval, Arnaud Gohier, David Brown, Karine Audouze, Olivier Taboureau
Summary: An integrated system pharmacology network and a chemogenomic library of 5000 small molecules have been developed to assist in target identification and mechanism deconvolution in phenotypic assays. This platform showcases the potential of combining advanced technologies in drug discovery.
JOURNAL OF CHEMINFORMATICS
(2021)
Article
Pharmacology & Pharmacy
Amitava Mitra, Mariam A. Ahmed, Rajesh Krishna, Kefeng Sun, Francis D. Gibbons, Olivia Campagne, Noha Rayad, Youssef M. Roman, Salwa Albusaysi, Maria Burian, Islam R. Younis
Summary: The approval of viral vector-based gene therapy products has shown promise in treating severe diseases, but their unique mechanism requires a complex clinical development plan. Due to the irreversible mode of action and limited understanding of genotype-phenotype relationship and disease progression in rare diseases, careful considerations must be given to the benefit-risk profile of gene therapy products. Quantitative tools, such as model-informed drug development, can aid in dose selection and optimizing clinical trial designs for adeno-associated virus (AAV) vector-based gene therapies.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Pharmacology & Pharmacy
Jennifer Walsh, Daniel Schaufelberger, Sonia Iurian, Sandra Klein, Hannah Batchelor, Roy Turner, Sveinbjorn Gizurarson, Luigi Boltri, Elisa Alessandrini, Catherine Tuleu
Summary: Improving global access to novel age-appropriate formulations for paediatric subsets is a priority to meet the needs of these patients. However, the development and introduction of paediatric formulations still lags behind adult products, primarily due to additional complexities associated with creating acceptable age-appropriate medicines.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Qiancheng Hu, Wenli Kang, Qingfeng Wang, Ting Luo
Summary: It is currently unclear which cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, combined with endocrine therapy, is the preferred treatment approach in patients with hormone receptor (HR)-positive, human epidermal receptor-2 (HER2) negative metastatic breast cancer. This study aims to evaluate the comparative efficacy, safety, and cost-effectiveness of different CDK4/6 inhibitors for metastatic breast cancer in first-line and second-line settings.
Article
Pharmacology & Pharmacy
Yuet Mei Khong, Jing Liu, Jack Cook, Vivek Purohit, Karen Thompson, Shailly Mehrotra, S. Y. Amy Cheung, Justin L. Hay, Elimika Pfuma Fletcher, Jian Wang, Hari Cheryl Sachs, Hao Zhu, Akhtar Siddiqui, Lea Cunningham, Arzu Selen
Summary: The workshop focused on advancing pediatric drug product development efforts through collaboration in various sectors. The clinical session highlighted the interconnection between pediatric formulation design, clinical development strategy, and pediatric clinical pharmacology. Collaborative strategic planning among stakeholders is essential for the success of pediatric drug product development, especially in the alignment between formulators and clinical pharmacology teams.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2021)
Review
Pharmacology & Pharmacy
Anthony W. Tolcher
Summary: Antibody Drug Conjugates (ADCs) are a type of drug combination that selectively delivers cytotoxic chemotherapy drugs to cancer cells. Over almost 30 years, the ADC platform has been established with 11 approved drugs and more in development. This review highlights the problems, solutions, and practical guidance for clinical investigators in ADC protocol design.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Grant Erickson, Michael McAnulty, Chelsea Powers, Thu-Lan Luong, Nicole R. Dobson, Carl E. Hunt
Summary: The 'ICAF' study investigates the stability of an enteral caffeine base solution used as a study drug for up to 6 months of storage. The study finds that the caffeine concentrations remain within 5% of the expected concentration when stored at room temperature. Multiple research pharmacies achieve accurate caffeine concentrations.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Chiara Campana, Rafael Dariolli, Mohamed Boutjdir, Eric A. Sobie
Summary: Cardiotoxicity testing is crucial in drug development, evaluating the risk of drugs inducing arrhythmias by predicting their effects on cardiac electrophysiology. Recent advances in safety pharmacology have taken a more integrative approach, considering the effects of drugs on multiple ion channels.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Eric S. White, Matthew Thomas, Susanne Stowasser, Kay Tetzlaff
Summary: Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium. Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease (ILD) characterized by respiratory failure and death. The development of pirfenidone and nintedanib has been a major breakthrough in the treatment of IPF, but there is still no cure for pulmonary fibrosis. Future treatment of pulmonary fibrosis may require more precision in targeting specific cell populations and exploring novel measures of efficacy.
FRONTIERS IN PHARMACOLOGY
(2022)
Editorial Material
Pharmacology & Pharmacy
Qi Liu, Mitra Ahadpour, Mitra Rocca, Shiew-Mei Huang
Summary: Clinical pharmacology focuses on variability in drug exposure and response in patients, contributing to understanding benefit-risk profiles. Future trends include the Model-Informed Drug Development program and using real-world data to generate real-world evidence.
Review
Pharmacology & Pharmacy
Dominik Buschmann, Veronika Mussack, James Brian Byrd
Summary: EVs are membrane nanovesicles secreted from living cells which have potential therapeutic activity and are being explored as drug delivery vehicles in preclinical investigations and early clinical trials. However, progress in EV-based drug delivery is hindered by heterogeneity of sample types and methods, as well as a persistent lack of standardization, validation, and comprehensive reporting.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Review
Pharmacology & Pharmacy
Julianne H. Tieu, Siddhee A. Sahasrabudhe, Paul J. Orchard, James C. Cloyd, Reena V. Kartha
Summary: X-linked adrenoleukodystrophy (X-ALD) is a rare genetic neurodegenerative disease with limited treatment options. Drug repurposing has been explored to find effective therapies, but none have been approved for use yet. Advanced translational and clinical pharmacological approaches may improve the success of repurposed drugs for X-ALD and other rare diseases.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Nur Hanisah Mustafa, Mahendran Sekar, Shivkanya Fuloria, M. Yasmin Begum, Siew Hua Gan, Nur Najihah Izzati Mat Rani, Subban Ravi, Kumarappan Chidambaram, Vetriselvan Subramaniyan, Kathiresan Sathasivam, Srikanth Jeyabalan, Subasini Uthirapathy, Sivasankaran Ponnusankar, Pei Teng Lum, Vijay Bhalla, Neeraj Kumar Fuloria
Summary: Sarsasapogenin, a natural steroidal sapogenin obtained from Anemarrhena asphodeloides Bunge, has shown diverse pharmacological activities including anti-inflammatory, anticancer, antidiabetic, anti-osteoclastogenic, neuroprotective activities, and potential in the treatment of precocious puberty. However, further comprehensive preclinical studies, clinical trials, and investigations into drug delivery, pharmacokinetics, adverse effects, and potential synergistic effects with other drugs are necessary for its development as a potential drug molecule.
Review
Pharmacology & Pharmacy
Avery McIntosh, Oleksandr Sverdlov, Li Yu, Petra Kaufmann
Summary: Cell and gene therapies have shown great potential recently, but their clinical trial design and development require different quantitative considerations than traditional drugs. Drug developers need to have interdisciplinary collaboration and learning abilities to navigate the unique development path of gene therapies.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
